How does IGF-1 relate to growth hormone in the GH-IGF-1 axis?

Growth hormone (GH) is secreted in pulsatile bursts from the anterior pituitary and acts on receptors throughout the body, most prominently in the liver. Hepatic GH receptor activation stimulates the synthesis and secretion of IGF-1, which then mediates the majority of GH anabolic and growth-promoting effects in peripheral tissues. This relationship is described as the GH-IGF-1 axis. IGF-1 also exerts negative feedback on GH secretion at the pituitary and hypothalamic level, forming a regulatory loop. Locally produced IGF-1 in muscle, bone, and other tissues contributes independently of circulating hepatic IGF-1, and this local production is also influenced by GH signalling. Peptides that stimulate GH release, such as CJC-1295, Ipamorelin, Sermorelin, and Hexarelin, therefore indirectly raise endogenous IGF-1 levels through this axis.

How does BPC-157 differ from IGF-1 in growth factor activity?

IGF-1 is a direct growth factor: it binds the IGF-1 receptor (a receptor tyrosine kinase) and directly activates downstream signalling cascades including PI3K-Akt and MAPK-ERK, driving cell proliferation, differentiation, and survival in muscle, bone, and other tissues. BPC-157, by contrast, does not itself bind a known growth factor receptor as a primary mechanism. Instead, it is reported to upregulate the expression of growth factors including vascular endothelial growth factor (VEGF), fibroblast growth factors (FGFs), and platelet-derived growth factor (PDGF) in relevant tissue compartments, promoting angiogenesis and repair indirectly through growth factor induction rather than direct receptor agonism. The two peptides therefore act at different levels of growth factor signalling: IGF-1 as a direct growth factor ligand, and BPC-157 as a modulator that influences growth factor expression.

What is the long-term risk concern with chronic IGF-1 elevation?

IGF-1 is a potent mitogenic signal that promotes cell proliferation and inhibits apoptosis. Chronic elevation of IGF-1 has been associated in epidemiological studies with increased risk of certain cancers, particularly colorectal, prostate, and breast cancers, though causal directionality remains debated. Prolonged supraphysiological IGF-1 exposure is also associated with acromegalic features including jaw and brow changes, soft tissue swelling, and visceral organ enlargement. Paradoxical insulin resistance has been reported with chronic IGF-1 use, contrary to its acute glucose-lowering effect. Most anecdotal research accounts describe short cycle lengths with off-periods to limit cumulative exposure. BPC-157 does not carry documented mitogenic risk at the doses reported in anecdotal research, as its mechanism of action is growth factor modulation rather than direct receptor agonism.

Peptide class

Growth Factor Peptides

Peptides that act directly as growth factors or that upregulate growth factor signalling, studied for anabolic, repair, and regenerative effects in muscle, connective tissue, and vasculature.

Compound	Mechanism	Primary reported use	Profile
IGF-1 (Insulin-like Growth Factor 1)	Direct IGF-1 receptor agonist; activates PI3K-Akt and MAPK-ERK; liver-derived mediator of GH anabolic effects	Muscle hypertrophy, satellite cell activation, skeletal growth, recovery	View profile
BPC-157	Upregulates VEGF, FGF, and PDGF expression; promotes angiogenesis and NO modulation; derived from gastric protein	Tendon, gut, and nerve repair; angiogenesis; systemic healing	View profile

How This Class Works

Growth factor peptides encompass compounds that either act directly as growth factor ligands or that modulate the expression and availability of endogenous growth factors. The archetype of the direct growth factor subgroup is IGF-1 (Insulin-like Growth Factor 1), a 70-amino acid peptide produced predominantly in the liver in response to growth hormone receptor activation. IGF-1 binds the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase, triggering autophosphorylation and activation of two principal downstream signalling cascades: the PI3K-Akt pathway, which promotes protein synthesis, glucose uptake, and cell survival; and the MAPK-ERK pathway, which drives cell proliferation and differentiation. In muscle tissue, IGF-1 activates satellite cells (muscle stem cells) and drives myonuclear accretion, the primary mechanism of skeletal muscle hypertrophy at the molecular level. The GH-IGF-1 axis connects pituitary-derived growth hormone to peripheral anabolic effects through hepatic IGF-1 production, and locally expressed IGF-1 in muscle and bone contributes additional autocrine and paracrine anabolic signalling independent of circulating levels.

BPC-157 represents a growth factor modulator rather than a direct growth factor. Derived from a partial sequence of human gastric juice protein BPC, it is a synthetic 15-amino acid pentadecapeptide with documented effects on angiogenesis and tissue repair across a range of preclinical models. Its reported mechanism involves upregulation of vascular endothelial growth factor (VEGF) and its receptors, as well as fibroblast growth factors (FGF) and platelet-derived growth factor (PDGF), promoting the formation of new blood vessels (angiogenesis) at injury sites. BPC-157 also interacts with the nitric oxide (NO) system, modulating vascular tone and potentially contributing to the repair of gastrointestinal and connective tissue. Unlike IGF-1, BPC-157 does not directly activate receptor tyrosine kinases as its primary mechanism; it instead modulates the growth factor milieu within target tissues.

These two mechanisms are complementary in healing-focused research contexts. BPC-157 promotes vascular supply (angiogenesis) and growth factor expression, while IGF-1 drives the downstream anabolic and proliferative responses that depend on that growth factor signalling. Neither has received regulatory approval for human therapeutic use; both are available as research chemicals and are reported in anecdotal research accounts, often in combination protocols targeting connective tissue repair.

Research Context

IGF-1 was characterised in the late 1970s as the downstream mediator of growth hormone anabolic action, initially termed somatomedin C. Its receptor, IGF-1R, was cloned in the 1980s and shown to share substantial homology with the insulin receptor. The IGF-1 axis has been extensively investigated in oncology, where elevated circulating IGF-1 has been associated in epidemiological studies with risk of colorectal, prostate, and breast cancers. In the context of human growth disorders, recombinant human IGF-1 (mecasermin, Increlex) has received FDA approval for growth failure in children with severe primary IGF-1 deficiency. Outside of this indication, IGF-1 administration is not approved and is prohibited in competitive sport by the World Anti-Doping Agency (WADA). Research in muscle biology and aging has investigated whether IGF-1 repletion may attenuate age-related muscle loss (sarcopenia); results in human studies have been mixed.

BPC-157 has been studied primarily in rodent models, where it has demonstrated consistent effects on tendon healing, gastrointestinal mucosal repair, nerve repair, and angiogenesis across numerous published preclinical studies originating largely from the group of Sikiric et al. at the University of Zagreb. No Phase 2 or Phase 3 human clinical trials for BPC-157 have been completed and published at the time of writing; the compound remains a research chemical without regulatory approval in any jurisdiction. Its combination with TB-500 in healing research contexts is widely described in anecdotal community protocols, combining BPC-157 angiogenic and growth factor activity with TB-500 actin-sequestration and cell migration effects.

Individual Compound Notes

IGF-1

Available in native form (plasma half-life approximately 10 minutes) and as IGF-1 LR3, an analogue with reduced IGFBP binding affinity and a half-life of 12 to 15 hours. IGF-1 LR3 is the more commonly described form in anecdotal research accounts. Common reported doses range from 20 to 100 mcg subcutaneously or intramuscularly, often in 4 to 8 week cycles. Hypoglycaemia risk requires carbohydrate co-administration at time of injection. Prohibited by WADA. FDA-approved only for severe primary IGF-1 deficiency in paediatric growth failure.

BPC-157

Commonly reported doses of 200 to 500 mcg subcutaneously or intramuscularly, with oral administration also used in gut-targeted research applications. Extensive preclinical evidence base; no approved pharmaceutical formulation. Frequently combined with TB-500 in anecdotal healing protocols. The combination targets complementary repair mechanisms: BPC-157 for growth factor induction and angiogenesis, TB-500 for cell migration via actin dynamics.